The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Sep 7, 2018

Warren Rowe, Xiaoqian Cheng, Lawan Ly, Taisen Zhuang, Giacomo Basadonna, Barry Trink, Michael Keidar, and Jerome Canady
Malignant solid tumors are characterized by high recurrence rates and low five-year survival
rates. Stage IV renal adenocarcinoma presents an extremely low five-year survival rate of 0–10% [1],
while the recurrence rate may be as high as 23% [2]. While the recurrence rate of colorectal carcinoma
is similar to that of renal adenocarcinoma at 19.4% to 21.6%, the five-year survival rate is significantly
higher at 88.6% to 89.4% [3]. Pancreatic ductal adenocarcinoma has an extremely low survival rate
of 10% to 28% [4] after one year due to a very high recurrence rate of 65.5% [5]. The resulting 5-year
survival rate is dismal at 6% in the United States and Europe [6]. Serous epithelial ovarian carcinoma
has a very low five-year survival rate of 42% for stage III and 26% for stage IV [7] with a 19% recurrence
rate [8]. Esophageal adenocarcinoma represents a similarly low five-year survival rate of 33% to
44% [9], depending on the treatment used, and can result in a recurrence rate as high as 43.2% [10].